Business
Jacobio Pharma Announces 2024 Annual Results
Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones.
About this update from Jacobio Pharmaceuticals Group Co., Ltd.
[{"type":"text","content":"BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones.","length":441,"tagName":"p"},{"type":"text","content":""2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the China rights of glecirasib and the SHP2 inhibitor sitneprotafib to our partner. This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead to 2025, glecirasib is expected to receive the official approval for marking, which will continuously generate cash flow to invest in Jacobio' subsequent pipeline."","length":650,"tagName":"p"},{"type":"text","content":"Development of core clinical stage products","length":43,"tagName":"p"},{"type":"text","content":"Glecirasib (JAB-21822, KRAS G12C inhibitor) and sitneprotafib (JAB-3312, SHP2 inhibitor)","length":88,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The commercialization and further clinical development in China of glecirasib and sitneprotafib were licensed to Allist on August 30, 2024.","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-small cell lung cancer (NSCLC)","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The NDA application of glecirasib monotherapy in second-line and above NSCLC was submitted to the CDE (China Drug Evaluation Center) in May 2024 and the priority review designation was granted in the same month. Glecirasib is expected to be approved in the first half of 2025.","length":281,"tagName":"p"}]},{"val":[{"type":"text","content":"The Phase III pivotal trial of glecirasib combined with sitneprotafib in front-line NSCLC enrolled the first patient in China on August 7, 2024.","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"len...